Paul Sephton

646 total citations
7 papers, 362 citations indexed

About

Paul Sephton is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Paul Sephton has authored 7 papers receiving a total of 362 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 2 papers in Genetics and 1 paper in Cardiology and Cardiovascular Medicine. Recurrent topics in Paul Sephton's work include Pulmonary Hypertension Research and Treatments (6 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (2 papers). Paul Sephton is often cited by papers focused on Pulmonary Hypertension Research and Treatments (6 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (2 papers). Paul Sephton collaborates with scholars based in United Kingdom, Australia and India. Paul Sephton's co-authors include Robin Condliffe, Judith Hurdman, Ian Sabroe, Neil Hamilton, Mehmet Ata Akıl, L. O’Toole, Charlie Elliot, C. Billings, Jim M. Wild and David Capener and has published in prestigious journals such as European Respiratory Journal, Thorax and European Journal of Clinical Microbiology & Infectious Diseases.

In The Last Decade

Paul Sephton

5 papers receiving 357 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Sephton United Kingdom 3 353 212 70 30 28 7 362
Rubina Khair United States 7 276 0.8× 165 0.8× 48 0.7× 29 1.0× 91 3.3× 10 318
J. Deague Australia 6 252 0.7× 202 1.0× 32 0.5× 27 0.9× 58 2.1× 10 344
J. Lemarié France 6 253 0.7× 195 0.9× 54 0.8× 13 0.4× 23 0.8× 11 278
J.-L. Jagot France 4 354 1.0× 216 1.0× 79 1.1× 17 0.6× 30 1.1× 8 374
Martha Kingman United States 9 262 0.7× 194 0.9× 41 0.6× 19 0.6× 7 0.3× 21 305
David Ambrož Czechia 10 254 0.7× 198 0.9× 60 0.9× 16 0.5× 13 0.5× 40 300
Pablo Sepúlveda Chile 8 137 0.4× 167 0.8× 26 0.4× 16 0.5× 9 0.3× 29 236
Katsumasa Miyaji Japan 10 349 1.0× 261 1.2× 108 1.5× 30 1.0× 5 0.2× 22 390
Onno A. Spruijt Netherlands 11 376 1.1× 337 1.6× 20 0.3× 107 3.6× 11 0.4× 20 459
Katarina Zeder Austria 8 237 0.7× 124 0.6× 13 0.2× 14 0.5× 8 0.3× 28 266

Countries citing papers authored by Paul Sephton

Since Specialization
Citations

This map shows the geographic impact of Paul Sephton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Sephton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Sephton more than expected).

Fields of papers citing papers by Paul Sephton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Sephton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Sephton. The network helps show where Paul Sephton may publish in the future.

Co-authorship network of co-authors of Paul Sephton

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Sephton. A scholar is included among the top collaborators of Paul Sephton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Sephton. Paul Sephton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
2.
Yorke, Janelle, Christi Deaton, Malcolm Campbell, et al.. (2018). Symptom severity and its effect on health-related quality of life over time in patients with pulmonary hypertension: a multisite longitudinal cohort study. BMJ Open Respiratory Research. 5(1). e000263–e000263. 37 indexed citations
3.
Billings, C., R. Thompson, Judith Hurdman, et al.. (2016). P28 Chronic thromboembolic pulmonary hypertension: long term outcomes in surgical and non-surgical patients. Thorax. 71(Suppl 3). A98.1–A98.
4.
Yorke, Janelle, Iain Armstrong, Christi Deaton, et al.. (2015). Patient rated WHO functional class and psychological distress are strongly associated with dyspnoea in pulmonary hypertension. Research Explorer (The University of Manchester). PA331–PA331. 1 indexed citations
5.
Yorke, Janelle, et al.. (2014). Self-reported adherence to pulmonary hypertension medications: Preliminary results from a longitudinal cohort study. European Respiratory Journal. 44(Suppl 58). 1414–1414. 2 indexed citations
6.
Sammut, D., Charles Elliot, David G. Kiely, et al.. (2013). Central venous catheter-related blood stream infections in patients receiving intravenous iloprost for pulmonary hypertension. European Journal of Clinical Microbiology & Infectious Diseases. 32(7). 883–889. 13 indexed citations
7.
Hurdman, Judith, Robin Condliffe, Charlie Elliot, et al.. (2011). ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. European Respiratory Journal. 39(4). 945–955. 309 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026